Pharmacology of calcineurin antagonists

M. H. Kapturczak, H. U. Meier-Kriesche, B. Kaplan

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Cyclosporine and tacrolimus share the same pharmacodynamic property of activated T-cell suppression via inhibition of calcineurin. The introduction of these drugs to the immunosuppressive repertoire of transplant management has greatly improved the outcomes in organ transplantation and constitutes arguably one of the major breakthroughs in modern medicine. To this date, calcineurin inhibitors are the mainstay of prevention of allograft rejection. The experience gained from the laboratory and clinical use of cyclosporine and tacrolimus has greatly advanced our knowledge about the nature of many aspects of immune response. However, the clinical practice still struggles with the shortcomings of these drugs: the significant inter- and intraindividual variability of their pharmacokinetics, the unpredictability of their pharmacodynamic effects, as well as complexity of interactions with other agents in transplant recipients. This article briefly reviews the pharmacological aspects of calcineurin antagonists as they relate to the mode of action and pharmacokinetics as well as drug interactions and monitoring.

Original languageEnglish (US)
JournalTransplantation Proceedings
Volume36
Issue number2 SUPPL.
DOIs
StatePublished - Mar 2004
Externally publishedYes

Fingerprint

Tacrolimus
Cyclosporine
Pharmacokinetics
Pharmacology
Modern 1601-history
Drug Monitoring
Calcineurin
Organ Transplantation
Immunosuppressive Agents
Drug Interactions
Pharmaceutical Preparations
Allografts
T-Lymphocytes
Transplants
Calcineurin Inhibitors
Transplant Recipients

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Kapturczak, M. H., Meier-Kriesche, H. U., & Kaplan, B. (2004). Pharmacology of calcineurin antagonists. Transplantation Proceedings, 36(2 SUPPL.). https://doi.org/10.1016/j.transproceed.2004.01.018

Pharmacology of calcineurin antagonists. / Kapturczak, M. H.; Meier-Kriesche, H. U.; Kaplan, B.

In: Transplantation Proceedings, Vol. 36, No. 2 SUPPL., 03.2004.

Research output: Contribution to journalArticle

Kapturczak, MH, Meier-Kriesche, HU & Kaplan, B 2004, 'Pharmacology of calcineurin antagonists', Transplantation Proceedings, vol. 36, no. 2 SUPPL.. https://doi.org/10.1016/j.transproceed.2004.01.018
Kapturczak, M. H. ; Meier-Kriesche, H. U. ; Kaplan, B. / Pharmacology of calcineurin antagonists. In: Transplantation Proceedings. 2004 ; Vol. 36, No. 2 SUPPL.
@article{f01c31e5b4fb46ad89e8725b038571a9,
title = "Pharmacology of calcineurin antagonists",
abstract = "Cyclosporine and tacrolimus share the same pharmacodynamic property of activated T-cell suppression via inhibition of calcineurin. The introduction of these drugs to the immunosuppressive repertoire of transplant management has greatly improved the outcomes in organ transplantation and constitutes arguably one of the major breakthroughs in modern medicine. To this date, calcineurin inhibitors are the mainstay of prevention of allograft rejection. The experience gained from the laboratory and clinical use of cyclosporine and tacrolimus has greatly advanced our knowledge about the nature of many aspects of immune response. However, the clinical practice still struggles with the shortcomings of these drugs: the significant inter- and intraindividual variability of their pharmacokinetics, the unpredictability of their pharmacodynamic effects, as well as complexity of interactions with other agents in transplant recipients. This article briefly reviews the pharmacological aspects of calcineurin antagonists as they relate to the mode of action and pharmacokinetics as well as drug interactions and monitoring.",
author = "Kapturczak, {M. H.} and Meier-Kriesche, {H. U.} and B. Kaplan",
year = "2004",
month = "3",
doi = "10.1016/j.transproceed.2004.01.018",
language = "English (US)",
volume = "36",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "2 SUPPL.",

}

TY - JOUR

T1 - Pharmacology of calcineurin antagonists

AU - Kapturczak, M. H.

AU - Meier-Kriesche, H. U.

AU - Kaplan, B.

PY - 2004/3

Y1 - 2004/3

N2 - Cyclosporine and tacrolimus share the same pharmacodynamic property of activated T-cell suppression via inhibition of calcineurin. The introduction of these drugs to the immunosuppressive repertoire of transplant management has greatly improved the outcomes in organ transplantation and constitutes arguably one of the major breakthroughs in modern medicine. To this date, calcineurin inhibitors are the mainstay of prevention of allograft rejection. The experience gained from the laboratory and clinical use of cyclosporine and tacrolimus has greatly advanced our knowledge about the nature of many aspects of immune response. However, the clinical practice still struggles with the shortcomings of these drugs: the significant inter- and intraindividual variability of their pharmacokinetics, the unpredictability of their pharmacodynamic effects, as well as complexity of interactions with other agents in transplant recipients. This article briefly reviews the pharmacological aspects of calcineurin antagonists as they relate to the mode of action and pharmacokinetics as well as drug interactions and monitoring.

AB - Cyclosporine and tacrolimus share the same pharmacodynamic property of activated T-cell suppression via inhibition of calcineurin. The introduction of these drugs to the immunosuppressive repertoire of transplant management has greatly improved the outcomes in organ transplantation and constitutes arguably one of the major breakthroughs in modern medicine. To this date, calcineurin inhibitors are the mainstay of prevention of allograft rejection. The experience gained from the laboratory and clinical use of cyclosporine and tacrolimus has greatly advanced our knowledge about the nature of many aspects of immune response. However, the clinical practice still struggles with the shortcomings of these drugs: the significant inter- and intraindividual variability of their pharmacokinetics, the unpredictability of their pharmacodynamic effects, as well as complexity of interactions with other agents in transplant recipients. This article briefly reviews the pharmacological aspects of calcineurin antagonists as they relate to the mode of action and pharmacokinetics as well as drug interactions and monitoring.

UR - http://www.scopus.com/inward/record.url?scp=1642317043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642317043&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.01.018

DO - 10.1016/j.transproceed.2004.01.018

M3 - Article

VL - 36

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 2 SUPPL.

ER -